COMPANY
Progentec Diagnostics
Funding and NIH signals
- NIH award NIH awarded $895K (SBIR commercialization 5SB1AI184309-03, continuation, notice Jun 12, 2026). NIH RePORTER 5SB1AI184309-03 (Jun 12, 2026)
Evidence (1 event)
- Jun 12, 2026 · NIH RePORTER 5SB1AI184309-03
Organization: PROGENTEC DIAGNOSTICS, INC.; City/State: Oklahoma City, OK; Project number: 5SB1AI184309-03; Activity code: SB1; Fiscal year: 2026; Award notice date: 2026-06-12; FY total cost (award amount): 895140; Administering IC: National Institute of Allergy and Infectious Diseases; Project title: Commercialization Readiness of Immune Mediator Based Blood Tests that Inform Concurrent and Future Clinical Disease Activity in Systemic Lupus Erythematosus (SLE); Organization type: Domestic For-Profits
- Jun 12, 2026 · NIH RePORTER 5SB1AI184309-03
Timeline
- Grant Government grant — SBIR: $895,140 (annual award, as published), announced Jun 12, 2026. Agency: NIH/NIAID. Source: government award database. source ↗
- Grant Government grant — SBIR: $895,140 (annual award, as published), announced Apr 28, 2025. Agency: NIH/NIAID. Source: government award database. source ↗
- Trial start —: Mobile Study to Measure and Predict Lupus Disease Activity Using Digital Signals source ↗
- Trial start —: Translation of a Diagnostic Test for Lupus Flare Prediction From Bench to Clinic source ↗
Funding
- Government grant — SBIR: $895,140 (annual award, as published), announced Jun 12, 2026. Agency: NIH/NIAID. Source: government award database. source ↗
- Government grant — SBIR: $895,140 (annual award, as published), announced Apr 28, 2025. Agency: NIH/NIAID. Source: government award database. source ↗
Clinical trials (lead sponsor) 2
| Record | Title | Phase | Status | Start | Primary completion |
|---|---|---|---|---|---|
| NCT04018222 | Translation of a Diagnostic Test for Lupus Flare Prediction From Bench to Clinic | Not listed | Unknown status (ClinicalTrials.gov) | May 31, 2019 | Dec 31, 2020 (estimated) |
| NCT04449653 | Mobile Study to Measure and Predict Lupus Disease Activity Using Digital Signals | Not listed | Unknown status (ClinicalTrials.gov) | Apr 28, 2020 | Dec 31, 2020 (estimated) |
NIH awards 4
- NIH award 1SB1AI184309-01 FY2024: $895,140 awarded for that fiscal year; activity SB1 (SBIR); PI MUNROE, MELISSA E; recipient as written: PROGENTEC DIAGNOSTICS, INC., Oklahoma City, OK. Commercialization Readiness of source ↗
- NIH award 5R44AI142967-03 FY2021: $742,933 awarded for that fiscal year; activity R44 (SBIR); PI MUNROE, MELISSA E; recipient as written: PROGENTEC DIAGNOSTICS, INC., Oklahoma City, OK. Development of Immune Mediator source ↗
- NIH award 4R44AI142967-02 FY2020: $742,933 awarded for that fiscal year; activity R44 (SBIR); PI MUNROE, MELISSA E; recipient as written: PROGENTEC DIAGNOSTICS, INC., Oklahoma City, OK. Development of Immune Mediator source ↗
- NIH award 1R44AI142967-01A1 FY2019: $225,000 awarded for that fiscal year; activity R44 (SBIR); PI MUNROE, MELISSA E; recipient as written: PROGENTEC DIAGNOSTICS, INC., Oklahoma City, OK. Development of Immune Mediat source ↗